公开(公告)号：WO2017112824A2

公开(公告)日：2017-06-29

申请号：PCT/US2016/068138

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： YIE, Junming ,  SHI, Donghui ,  LLOYD, David J. ,  WANG, Jinghong ,  SIVITS, JR., Glenn N. ,  VENIANT-ELLISON, Murielle M. ,  KOMOROWSKI, Renee ,  AGRAWAL, Neeraj ,  BATES, Darren L. ,  CLAVETTE, Brandon C. P. ,  FOLTZ, Ian N. ,  HO, Shu-yin ,  MURAWSKY, Christopher ,  MIN, Xiaoshan ,  WANG, Zhulun

IPC: C07K16/28

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Abstract translation: 提供了使用对GIPR多肽特异的抗原结合蛋白治疗代谢疾病和病症的方法。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰​​岛素水平升高和糖尿病性肾病。 在某些实施方案中，抗原结合蛋白与GLP-1受体激动剂联合给药。

公开(公告)号：WO2018237095A1

公开(公告)日：2018-12-27

申请号：PCT/US2018/038634

申请日：2018-06-20

Applicant: AMGEN INC.

Inventor： WALKER, Kenneth W. ,  HOLDER, Jerry Ryan ,  LLOYD, David J. ,  LU, Shu-Chen ,  VENIANT-ELLISON, Murielle M. ,  STANISLAUS, Shanaka

IPC: C07K16/28 ,  A61K38/26

Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-l/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

公开(公告)号：WO2018136440A1

公开(公告)日：2018-07-26

申请号：PCT/US2018/013918

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： CHENG, Yuan ,  NETIROJJANAKUL, Chawita ,  HOLDER, Jerry Ryan ,  WU, Bin ,  FALSEY, James R. ,  HERBERICH, Bradley J. ,  SHAM, Kelvin ,  MIRANDA, Leslie P. ,  LU, Shu-Chen ,  VENIANT-ELLISON, Murielle M. ,  STANISLAUS, Shanaka ,  YIE, Junming ,  XU, Jing

IPC: A61K39/395 ,  C07K16/28 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：WO2017112824A8

公开(公告)日：2017-06-29

申请号：PCT/US2016/068138

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： YIE, Junming ,  SHI, Donghui ,  LLOYD, David J. ,  WANG, Jinghong ,  SIVITS, JR., Glenn N. ,  VENIANT-ELLISON, Murielle M. ,  KOMOROWSKI, Renee ,  AGRAWAL, Neeraj ,  BATES, Darren L. ,  CLAVETTE, Brandon C. P. ,  FOLTZ, Ian N. ,  HO, Shu-yin ,  MURAWSKY, Christopher ,  MIN, Xiaoshan ,  WANG, Zhulun

IPC: C07K16/28 ,  A61K38/26 ,  A61K39/395 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.